Home / Stocks / Kilitch Drugs India Ltd
KILITCH

Kilitch Drugs India Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹236.95

Change

+6.83 (2.97%)

Open

₹233.98

Prev. Close

₹230.12

Day High

₹240.0

Day Low

₹228.82

Volume Analysis

Traded

34,345

Delivered

13,567

Delivery %

39.5%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (38.1%)
  • •Strong 3-year revenue growth (18.8%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹252.88 ₹246.44 ₹241.7 ₹235.26 ₹230.52 ₹224.08 ₹219.34
Fibonacci ₹246.44 ₹242.17 ₹239.53 ₹235.26 ₹230.99 ₹228.35 ₹224.08
Camarilla ₹240.02 ₹239.0 ₹237.97 ₹235.26 ₹235.93 ₹234.9 ₹233.88

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-34.06%

1 Week

+18.11%

1 Month

+16.28%

3 Months

+45.97%

6 Months

+30.0%

1 Year

-34.64%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹126.57

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

7.9%

Net margin 9.62% × asset turnover 0.51x × equity multiplier 1.61x

Company Overview

Sector

Healthcare

Market Cap

₹805 Cr

P/E (TTM)

33.4

ROE

10.6%

Book Value

₹82.5

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Kilitch Drugs India Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (98/100), while Liquidity (20/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (38.1%).

TopFund Score — Fundamentals Quality

60/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

98

Growth

98

Valuation

39

Cash Flow

58

Corporate Governance

43

Momentum

75

Institutional Ownership

30

Business Quality

61

Risk & Volatility

25

Liquidity

20

From Screener.in

  • +Company has delivered good profit growth of 54.7% CAGR over last 5 years
  • +Company's median sales growth is 28.4% of last 10 years
  • −Stock is trading at 2.79 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 10.2% over last 3 years.
  • −Company has high debtors of 186 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 41 32 45 33 47 56 61 43 49 54 90 45 50
Expenses + 33 30 38 32 41 47 47 40 44 48 67 42 44
Operating Profit 9 2 7 2 6 9 15 3 5 6 22 3 7
OPM % 20.92% 7.17% 15.8% 4.96% 12.85% 15.54% 23.83% 7.56% 10.3% 11.43% 24.71% 6.55% 13.32%
Other Income + 0 3 0 3 5 2 2 3 7 2 0 3 2
Interest 2 2 1 2 0 1 2 2 1 1 1 1 2
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 4
Profit before tax 7 3 5 2 10 8 14 3 9 6 20 4 3
Tax % 24.93% 38.16% 30.57% 93.33% 16.73% 32.0% 26.23% 34.49% 14.47% 22.9% 26.37% 48.84% 57.49%
Net Profit + 5 2 4 0 9 6 10 2 8 4 15 2 1
EPS in Rs 1 1 1 0 3 2 3 1 2 1 4 1 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 34 6 -1 -9 15 77 37 29 3 -4 46 4 3

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 19 21 27 51 82 53 68 114 140 154 198 235 239
Expenses + 21 25 28 45 75 53 63 104 122 130 167 198 201
Operating Profit -2 -4 -1 6 7 0 5 10 18 24 32 37 38
OPM % -9.0% -19.0% -2.0% 11.0% 9.0% 0.8% 8.0% 9.0% 13.0% 16.0% 16.0% 16.0% 16.0%
Other Income + 3 2 1 3 4 4 3 3 3 4 11 11 7
Interest 0 0 0 0 1 1 1 1 5 6 5 6 5
Depreciation 2 10 10 2 2 2 2 2 4 3 3 4 7
Profit before tax -1 -12 -9 6 9 2 5 10 12 19 34 39 33
Tax % -70.0% -4.0% -5.0% 16.0% 55.0% 48.0% 27.0% 35.0% 31.0% 30.0% 28.0% 24.0% —
Net Profit + 0 -11 -9 5 4 1 4 6 8 14 25 30 23
EPS in Rs 0 -4 -3 2 1 0 1 2 3 4 8 9 7
Dividend Payout % 0.0% 0.0% 0.0% 13.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 10 30 87 62 -35 28 67 22 11 28 19 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 107 95 88 98 106 103 112 124 136 160 186 245 254
Borrowings + 0 0 1 1 9 13 15 20 22 32 49 89 97
Other Liabilities + 7 8 11 15 13 12 61 50 46 32 61 89 79
Total Liabilities 127 117 113 128 144 143 203 210 220 240 313 458 464
Fixed Assets + 9 42 33 33 32 32 30 65 64 62 64 67 220
CWIP 0 0 1 3 20 30 65 3 4 6 47 140 0
Investments 72 49 53 56 53 52 60 71 62 72 72 75 80
Other Assets + 46 25 26 35 38 30 47 71 90 100 129 176 164
Total Assets 127 117 113 128 144 143 203 210 220 240 313 458 464
Equity Capital 13 13 13 14 15 15 15 16 16 16 16 35 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -8 17 1 1 0 4 46 6 3 -2 18 24
Cash from Investing Activity + -31 -20 -2 -4 -14 -10 -38 -15 8 -8 -40 -100
Cash from Financing Activity + 0 0 0 6 17 1 2 7 -1 9 13 82
Net Cash Flow -39 -2 0 2 3 -5 10 -2 10 -1 -9 6
Free Cash Flow -10 -26 0 -2 -19 -6 9 -2 -1 -8 -29 -76
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 430 -442 -202 25 60 1,598 877 79 39 23 82 92

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.23% → 63.77%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 30.76% 30.77% 30.77% 30.77% 30.76% 30.77% 30.77% 36.22% 36.23% 36.22% 36.11% 35.62%
Promoters 69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 69.23% 63.77% 63.77% 63.77% 63.77% 63.77%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.12% 0.1%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Kilitch Drugs India Ltd (this stock) 805 33.4 2.79 10.6%
Shree Ganesh Remedies Ltd 798 65.9 4.79 10.8%
Zim Laboratories Limited 756 365.0 2.59 1.59%
Health X Platform Limited 862 510.0 1.36 0.44%
Gaudium Ivf N Women H L 740 32.0 4.55 24.6%
Themis Medicare Ltd. 929 624.0 2.33 0.41%
Wanbury Limited 676 20.3 4.3 76.5%

Which Mutual Funds Hold Kilitch Drugs India Ltd?

Frequently Asked Questions about Kilitch Drugs India Ltd

Community Sentiment

What are other investors saying about Kilitch Drugs India Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.